Literature DB >> 16713033

Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.

Christoph Eisenbach1, Anne Freyse, Catalin M Lupu, Kilian Weigand, Evelyn Ernst, Birgit Hoyler, Wolfgang Stremmel, Joachim J Bugert, Jens Encke.   

Abstract

Surrogate infections with HCV-recombinant vaccinia viruses (HCV-rVV) are a standard method to test the efficacy of hepatitis C virus (HCV) vaccine candidates in the mouse model. We established a panel of 16 HCV-rVV expressing the nonstructural protein 3 (NS3) of HCV genotypes 1a, 1b, 2, 3 and 4. Mice immunized with recombinant NS3 protein derived from HCV genotype 1b were challenged with the rVV. rVV-titers decreased up to 54-fold after subtype 1b challenge and up to 8.5-fold after subtype 1a challenge. No change was detected for genotype 2, 3, or 4. Our model is a convenient and reliable tool to analyze the induction of cross-genotype immunity by experimental vaccination of mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16713033     DOI: 10.1016/j.vaccine.2006.04.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines.

Authors:  Wenbo Yu; Branka Grubor-Bauk; Ranajoy Mullick; Saumitra Das; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead.

Authors:  Marianne Mikkelsen; Jens Bukh
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.